Verastem (VSTM) Other financing activities (2011 - 2026)
Verastem (VSTM) posted quarterly Other financing activities of $29.4 million for Q1 2026, up 619.35% year-over-year from $4.1 million in Q1 2025, and up 146755.0% quarter-over-quarter from $20000.0 in Q4 2025.
Powered by 
Analysis
Verastem (VSTM) Other financing activities (2011 - 2026) Analysis & Trends
Verastem's Other financing activities history runs 15 years deep, the most recent figure standing at $29.4 million for Q1 2026.
- In Q1 2026, Other financing activities rose 619.35% year-over-year to $29.4 million; the TTM figure through Mar 2026 stood at $25.4 million (down 41.72% YoY), while the FY2025 annual figure was $116000.0, down 99.71% from the prior year.
- Other financing activities for Q1 2026 stood at $29.4 million, up from $20000.0 in the prior quarter.
- The five-year high for Other financing activities was $39.4 million in Q3 2024, with the low at -$13.7 million in Q3 2025.
- The 5-year median for Other financing activities is $92000.0 (2022), against an average of $5.3 million.
- The sharpest annual moves came in 2024 and 2025: Other financing activities soared 140521.43% in 2024, then plunged 134.91% in 2025.
- Verastem's Other financing activities stood at $90000.0 in 2022, then slumped by 68.89% to $28000.0 in 2023, then jumped by 140521.43% to $39.4 million in 2024, then slumped by 99.95% to $20000.0 in 2025, then surged by 146755.0% to $29.4 million in 2026.
- Business Quant data shows VSTM's Other financing activities at $29.4 million in Q1 2026, $20000.0 in Q4 2025, and -$13.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Verastem | 815.95 Mn | 679.59 Mn | 36.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 29.37 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 18.08 Mn |
| Jun 30, 2025 | 9.76 Mn |
| Mar 31, 2025 | 4.08 Mn |
| Sep 30, 2024 | 39.37 Mn |
| Jun 30, 2024 | 136,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Sep 30, 2023 | 28,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Sep 30, 2022 | 90,000.00 |
| Jun 30, 2022 | 92,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 8,000.00 |
| Sep 30, 2021 | 261,000.00 |
| Jun 30, 2021 | 518,000.00 |
| Mar 31, 2021 | 300,000.00 |
| Dec 31, 2020 | 1.05 Mn |
| Sep 30, 2020 | 147,000.00 |
| Jun 30, 2020 | 551,000.00 |